Tell Medicare to Cover Continuous Glucose Monitors for People with Diabetes

  • by: JDRF
  • recipient: Centers for Medicare and Medicaid Services
Diabetes technologies have the potential to transform the care of people with diabetes.

The continuous glucose monitor (CGM) has been shown to improve glucose control — preventing dangerous high and low blood sugars — and is recommended by national diabetes clinical guidelines and covered by nearly all private health plans.

However, Medicare does not yet cover CGM devices, leaving seniors with insulin-dependent diabetes vulnerable to high rates of hospitalization and emergency room visits.

In addition, coverage of this important technology by Medicare will also help advance artificial pancreas systems, of which CGM is an important component.

Medicare needs to hear from YOU that access to CGMs is vitally important.

Sign today, and your name will be included in the petition that will be formally submitted to Medicare.
Dear Medicare,

Continuous glucose monitors (CGMs) are a critical component of diabetes management for many people with insulin-dependent diabetes;

Use of a CGM demonstrates improved glucose control and reduces rates of dangerously low blood sugar levels (hypoglycemia) in adults, lowering the risk for diabetes-related complications such as: kidney disease, heart disease, nerve damage, blindness, seizures, coma and death;

CGM use is recommended by all leading diabetes professional societies and CGM technology is covered by nearly all private health plans; and

The CGM is an important component of future artificial pancreas technologies that will transform diabetes care.

Therefore, we the undersigned, urge Medicare to provide coverage for life-saving CGM technology for people with insulin-dependent diabetes.

[Your name]
Sign Petition
Sign Petition
You have JavaScript disabled. Without it, our site might not function properly.

Privacy Policy

By signing, you accept Care2's Terms of Service.
You can unsub at any time here.

Having problems signing this? Let us know.